Last reviewed · How we verify

Shenzhen Hornetcorn Bio-technology Company, LTD — Portfolio Competitive Intelligence Brief

Shenzhen Hornetcorn Bio-technology Company, LTD pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class
  2. Bio-Thera Solutions · 1 shared drug class
  3. Celgene · 1 shared drug class
  4. Celyad Oncology SA · 1 shared drug class
  5. Chongqing Precision Biotech Co., Ltd · 1 shared drug class
  6. EdiGene Inc. · 1 shared drug class
  7. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 shared drug class
  8. Akeso · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shenzhen Hornetcorn Bio-technology Company, LTD:

Cite this brief

Drug Landscape (2026). Shenzhen Hornetcorn Bio-technology Company, LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shenzhen-hornetcorn-bio-technology-company-ltd. Accessed 2026-05-18.

Related